12:00 AM
 | 
Apr 04, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

VX-770: Phase III data

The ongoing, double-blind, international Phase III ENVISION trial in 52 patients ages 6 to 11 carrying the G551D mutation in CFTR on at least 1 allele showed that twice-daily 150 mg oral VX-770 met the primary endpoint of significantly improving the mean absolute change in FEV1 from baseline to week 24 vs. placebo. Specifically, the mean absolute improvement in FEV1 at week 24 compared to placebo was 12.5% (p<0.0001). VX-770 also led to a mean relative improvement in FEV1 from baseline at week 24 of 17.4% compared to placebo (p<0.0001)....

Read the full 429 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >